

FINANCIAL RESULTS
for the first half of
2024

31/07/2024



KEY FIGURES

Summary

IN € MILLIONS	H1 2024	H1 2023	Growth	% Growth
Operating revenue(1)	329.3	380.8	(51.5)	-14%
Gross profit(2)	195.6	215.7	(20.0)	-9%
EBITDA(3)	69.9	97.1	(27.2)	-28%
EBIT(4)	56.5	85.2	(28.7)	-34%
Net profit(5)	44.3	66.6	(22.3)	-33%
Purchases of property, plant and equipment and intangible assets ("Capex")	18.7	18.2	0.5	3%
FCF(6)	11.2	35.1	(24.0)	-68%
Gross profit as % of operating revenue	59.4%	56.6%		2.8 pp
EBITDA as % of operating revenue	21.2%	25.5%		-4.3 pp
EBIT as % of operating revenue	17.1%	22.4%		-5.2 pp
Net profit as % of operating revenue	13.5%	17.5%		-4.0 pp
Capex as % of operating revenue	5.7%	4.8%		0.9 pp
FCF as % of operating revenue	3.4%	9.2%		-5.8 pp

	As of June 30, 2024	As of Dec 31, 2023	Growth	% Growth
Net debt (€m)(7)	74.7	38.6	36.1	93%

Note: certain numerical figures included in this document have been rounded. Therefore, discrepancies in tables between totals and the sums of the amounts listed may occur due to such rounding.

(1) Operating revenue refers to revenue.

(2) Gross profit calculated as revenue plus the recognition of government grants on non-financial non-current assets and other less change in inventories of finished goods and work in progress and raw materials and consumables used.

(3) EBITDA calculated as profit before interest, taxes, depreciation and amortization.

(4) EBIT calculated as profit before taxes and interest.

(5) Net profit refers to profit for the period.

(6) Free Cash Flow (FCF) calculated as net cash generated from operating activities less purchases of property, plant and equipment and intangible assets ("Capex") plus proceeds from sale of property, plant and equipment plus interest received.

(7) Net debt composed of equity securities, plus deposits, plus financial derivatives, plus cash and cash equivalents, less current and non-current financial debt.

The consolidated financial statements of Grupo ROVI for the first half of 2024 and the comparative information for 2023 (balance sheet) and for the first half of 2023 (consolidated income statement and cash flow statement) are attached to this report (see Appendix 1). There has been a limited review of the figures for the first half of 2024 and the first half of 2023 by the auditor. Likewise, the figures as of December 31, 2023 are audited figures.

CONTENTS

<u>HIGHLIGHTS FIRST HALF 2024</u>	<u>3</u>
<u>GROUP MANAGEMENT REPORT</u>	<u>8</u>
<u>INCOME STATEMENT</u>	<u>8</u>
<u>REVENUES</u>	<u>8</u>
<u>SPECIALTY PHARMACEUTICAL BUSINESS</u>	<u>10</u>
<u>LOW MOLECULAR WEIGHT HEPARINS</u>	<u>11</u>
<u>OTHER PRESCRIPTION-BASED PHARMACEUTICAL PRODUCTS</u>	<u>12</u>
<u>CONTRAST AGENTS AND OTHER HOSPITAL PRODUCTS</u>	<u>13</u>
<u>CDMO BUSINESS</u>	<u>13</u>
<u>OTHER INCOME</u>	<u>13</u>
<u>COSTS</u>	<u>13</u>
<u>GROSS PROFIT</u>	<u>14</u>
<u>RESEARCH AND DEVELOPMENT EXPENSES</u>	<u>14</u>
<u>SELLING, GENERAL AND ADMINISTRATIVE EXPENSES</u>	<u>14</u>
<u>DEPRECIATION</u>	<u>14</u>
<u>NET FINANCE RESULT</u>	<u>15</u>
<u>EFFECTIVE TAX RATE</u>	<u>15</u>
<u>FINANCIAL PERFORMANCE</u>	<u>15</u>
<u>DIVIDEND</u>	<u>17</u>
<u>FINANCIAL POSITION</u>	<u>18</u>
<u>LIQUIDITY</u>	<u>21</u>
<u>OUTLOOK</u>	<u>24</u>
<u>R&D UPDATE</u>	<u>24</u>
<u>ESG</u>	<u>25</u>
<u>KEY OPERATING AND FINANCIAL EVENTS</u>	<u>26</u>
<u>APPENDIX 1</u>	<u>33</u>
<u>APPENDIX 2</u>	<u>35</u>

HIGHLIGHTS FIRST HALF 2024


ROVI ACHIEVED OPERATING REVENUE OF 329.3 MILLION EUROS AND INCREASED ITS GROSS MARGIN BY 2.8 PERCENTAGE POINTS

- Operating revenue in the first half of 2024 was 329.3 million euros, a 14% decrease on the first half of 2023, mainly due to the performance of the CDMO business. This division generated (i) lower revenues from the manufacture of the COVID-19 vaccine in comparison to the first half of 2023, when ROVI (the "Company" or the "Group") had booked higher income related to the production of the "pandemic" COVID-19 vaccine; and, (ii) lower revenues related to the activities carried out to prepare the plant for the production of the vaccine under the agreement with Moderna.
- Positive evolution of Okedi® (Risperidone ISM®), which sales multiplied the 2023 first-half sales by 141% in the first half of 2024, totalling 12.5 million euros.
- ROVI expects Risperidone ISM® to reach potential sales of between 200 and 300 million euros globally in upcoming years and to become a significant player worldwide in the field of long-acting injectables to treat schizophrenia.
- Sales of the heparin franchise (low molecular weight heparins (LMWH) and other heparins) decreased by 2% to 120.7 million euros in the first half of 2024, mainly due to lower orders from enoxaparin partners. However, ROVI expects a greater concentration of orders from enoxaparin partners in the second half of 2024 compared to the first six months of the year. In addition, sales of the heparin franchise increased by 14% to 64.3 million euros in the second quarter of 2024 compared to the first quarter of 2024.
- Good performance of Neparvis®, sales of which increased by 13%, in the first half of 2024 compared to the same period of 2023, rising to 25.0 million euros.
- In April 2024, ROVI announced that its subsidiary ROIS entered into an agreement to support the manufacture of pre-filled syringes for a global pharmaceutical company. Under the terms of the agreement, ROIS will provide a high-speed production line at its San Sebastián de los Reyes facility in Madrid, with an estimated annual capacity of 100 million units. Commercial production is expected to commence in 2026, and as from 2027, which is expected to be the first full recurrent manufacturing year, ROVI's CDMO division expects to have a positive revenue impact with an increase ranging between 20% and 45% over 2023 sales.
- Gross margin was 59.4% in the first six months of 2024, an increase of 2.8 percentage points on the first half of 2023. This increase was mainly due to: (i) the decrease in the contribution to the manufacturing business (CDMO) of revenue relating to activities to prepare the plant to produce medicines under the agreement with Moderna, which contributed lower margins to Group sales; (ii) the increased contribution to the CDMO business by existing


customers (excluding Moderna), which contributed higher margins; and (iii) the increased contribution of sales of Okedi®, which added higher margins.

- Net profit was 44.3 million euros in the first half of 2024.
- The ROVI General Shareholders Meeting, held on 24 June 2024, approved the payment of a gross dividend of 1.1037 euros per share; which represents approximately a 35% pay-out. This dividend was paid on 10 July 2024.

REVENUE BY REGION (%)



REVENUE BY BUSINESS UNIT (€Mn)



OUTLOOK

For 2024, ROVI expects its operating revenue to **decrease by a mid-single-digit percentage** in comparison with 2023. Notwithstanding, there are certain factors that have been considered when calculating this guidance that, although they could be relevant to the estimates, are difficult to specify at present, including, among others:

1. First, the saturation of the National Health Systems due to the low vaccination ratios during the 2023 COVID-19 campaign could favour a more successful vaccination campaign in 2024. However, as of today's date, the Company is not in a position to forecast how demand and production might evolve for the remainder of the vaccination campaign in 2024.
2. Second, it is hoped that the expansion of the compounding, aseptic filling, inspection, labelling and packaging capacities at ROVI's facilities in Madrid and the current high demand for CDMO services in the market might favour obtaining new business, with the resulting sales impact. This would have to be taken into consideration but cannot be estimated at present.

END OF THE SHARE BUY-BACK PROGRAMME

On 11 June 2024, ROVI informed on the completion of the Buy-Back Programme launched on 26 July 2023. Under the framework of this programme, a total of 2,233,466 shares were acquired for an amount of 130.0 million euros, which represents approximately 4.3% of the share capital.

As notified when the Buy-Back Programme commenced, the purpose of the programme was to cancel shares of ROVI through a reduction of capital and, at the same time, to contribute to ROVI's shareholder remuneration by increasing the profit per share. The reduction of the capital will be carried out by cancelling 2,780,395 shares. The latter corresponds to (i) the shares repurchased within the framework of the aforementioned Buy-Back Programme, and (ii) part of the existing treasury shares, which total 546,929. The capital reduction was approved at the Ordinary General Shareholders' Meeting, held on 24 June 2024. The new amount of the share capital, after the shares mentioned have been cancelled and excluded from trading, will appear in the registers of the National Securities Market Commission and Iberclear a few days after registration of the deed of capital reduction. The Company will provide further information in due course (see further information on page 27).



Juan López-Belmonte Encina, Chairman and Chief Executive Officer of ROVI, said: "2024 is a year of transition and will be of crucial importance in establishing the bases for ROVI's future. We are undergoing a growth phase focused on reinforcing the company's internationalisation with Risperidone ISM®, the first innovative ROVI product based on ISM® technology, with which we forecast potential sales of between 200 and 300 million euros globally in upcoming years, and which we are confident will represent significant growth in our specialty pharmaceutical business. The positive reception of the product in the European countries where it has been launched, the recent FDA marketing authorisation for Risperidone ISM® in the United States and the approval of the product in Canada and Australia open up new growth opportunities

for us all over the world in the field of long-acting injectables to treat schizophrenia. Innovation is one of ROVI's hallmarks and the ISM® platform provides new channels for growth. We continue to progress with the phase 1 clinical trial of the three-monthly formulation of letrozole (Letrozole LEBE) and the phase 1 clinical trial in Europe of our three-monthly formulation of risperidone, reflecting a clear commitment to our ISM® technology. Additionally, in March 2024, we announced the incorporation of a new public-private investment vehicle, Terafront Farmatech, to develop advanced, innovative or emerging medicines, therapies and/or technologies jointly with Insud Pharma, S.L. and Invierte Economía Sostenible SICC, SME, S.A. (investment company of Centro para el Desarrollo Tecnológico Industrial EPE – CDTI). This represents an opportunity to contribute to placing Spain in a leading position in the clinical research into new therapies, with the capacity to translate this research into manufacturing and thus improve the availability of new therapies to patients. Regarding our industrial presence, we are continuing to invest in our plants to expand our production capacity. Specifically, we are conducting an investment project at the San Sebastián de los Reyes plant to increase this site's capacity to 500 million injectables in the coming years, which the Community of Madrid has classified as a strategic project. In addition, in June 2024 we received the European authorities' approval for the commencement of commercial activity at the new sodium heparin plant in Escúzar (Granada). With this new plant, we are increasing our capacities for the production of heparins, a medicine that is classified as essential by the World Health Organization ("WHO") and among the drugs included in the European Union's Critical Medicine Alliance, in which ROVI participates. Thus, ROVI is positioned as one of the largest pharmaceutical groups in Spain, with eight fully-integrated plants, five of which manufacture ROVI's own products, while three are engaged in contract development manufacturing operations. A ninth plant is currently under construction. Likewise, in January 2024, we received the FDA's approval to manufacture the active

ingredient of the COVID-19 vaccine at our Granada plant. This, together with the FDA approval received in September 2023 for our injectables manufacturing plants in Madrid, San Sebastián de los Reyes and Alcalá de Henares for the fill-and-finish of Moderna's COVID-19 vaccine syringes, demonstrates our commitment to the quality and safety of our service. In relation to our low-molecular-weight heparin ("LMWH") business, we aspire to become a global leader in this field. In this context, we continue to invest to become self-sufficient in obtaining crude heparin with the Glicopepton project and thus become a vertically integrated company in all the low-molecular-weight heparin manufacturing phases. We hope this investment will help us to increase the future margins of the heparin franchise."

GROUP MANAGEMENT REPORT

for the six-month period ending June 30th, 2024

INCOME STATEMENT

IN € MILLIONS	H1 2024	H1 2023	Growth	% Growth
Operating revenue(1)	329.3	380.8	(51.5)	-14%
Other income(2)	0.2	0.2	0.0	19%
Total revenue(3)	329.5	381.0	(51.5)	-14%
Cost of goods sold(4)	(133.9)	(165.3)	31.4	-19%
Gross profit(5)	195.6	215.7	(20.0)	-9%
<i>% margin(11)</i>	59.4%	56.6%		2.8 pp
R&D expenses(6)	(12.2)	(10.8)	(1.4)	13%
SG&A(7)	(113.5)	(107.8)	(5.7)	5%
ventures and associated companies	(0.02)	(0.01)	(0.01)	69%
EBITDA(8)	69.9	97.1	(27.2)	-28%
<i>% margin(11)</i>	21.2%	25.5%		-4.3 pp
EBIT(9)	56.5	85.2	(28.7)	-34%
<i>% margin(11)</i>	17.1%	22.4%		-5.2 pp
Finance Income/(Costs)	(0.3)	0.6	(1.0)	n.a.
Profit before income tax	56.1	85.8	(29.7)	-35%
Income tax	(11.8)	(19.2)	7.4	-38%
<i>Effective tax</i>	21.0%	22.4%		-1.3 pp
Net profit(10)	44.3	66.6	(22.3)	-33%
Net profit attributable to parent company	44.3	66.6	(22.3)	-33%
Profit attributable to minority interests	0.0	0.0	0.0	n.a.

(1) Operating revenue refers to revenue.

(2) Other income includes the recognition of government grants on non-financial non-current assets and other.

(3) Total revenue calculated as revenue plus the recognition of government grants on non-financial non-current assets and other.

(4) Cost of sales calculated as the amount of procurements plus that corresponding to the change in inventories of finished goods and work in progress and raw materials and consumables use.

(5) Gross profit calculated as revenue plus the recognition of government grants on non-financial non-current assets and other less change in inventories of finished goods and work in progress and raw materials and consumables used.

(6) R&D expenses are calculated as the sum of employee benefit expenses and other operating expenses related to scientific research and technological development.

(7) SG&A calculated as the amount of employee benefit expenses plus other operating expenses plus work carried out by the Group on non-current assets" minus research & development expenses.

(8) EBITDA calculated as profit before interest, taxes, depreciation and amortization.

(9) EBIT calculated as profit before taxes and interest.

(10) Net profit refers to profit for the period.

(11) The gross margin and the EBITDA and EBIT margins are calculated as the result of dividing the gross profit, the EBITDA and the EBIT, respectively, by revenue, expressed as a percentage.

REVENUES

Total revenue by business unit

IN € MILLIONS	H1 2024	H1 2023	Growth	% Growth
Specialty pharmaceutical business	210.5	208.6	1.9	1%
CDMO business	118.9	172.2	(53.4)	-31%
Operating revenue(1)	329.3	380.8	(51.5)	-14%
Other income(2)	0.2	0.2	0.0	19%
Total revenue(3)	329.5	381.0	(51.5)	-14%

(1) Operating revenue refers to revenue excluding the recognition of government grants on non-financial non-current assets and other.

(2) Other income includes the recognition of government grants on non-financial non-current assets and other.

(3) Total revenue calculated as operating revenue plus the recognition of government grants on non-financial non-current assets and other.

Operating revenue in the first half of 2024 was 329.3 million euros, a 14% decrease on the first half of 2023. This decrease was mainly caused by a drop in contribution of the CDMO business, sales of which fell to 118.9 million euros from 172.2 million euros in the first half of 2023, due to: (i) lower revenues from the manufacture of the COVID-19 vaccine in comparison to the first half of 2023, when ROVI had booked higher income related to the production of the "pandemic" COVID-19 vaccine; and, (ii) lower revenues related to the activities to prepare the plant for the production of the vaccine under the agreement with Moderna. However, sales from the specialty pharmaceutical business increased 1% to 210.5 million euros, compared to 208.6 million euros in the first half of 2023. **Total revenue** fell 14% to 329.5 million euros in the first half of 2024.

Sales outside Spain decreased 22% in the first half of 2024, compared to the first half of 2023, to 188.4 million euros, mainly due to the decrease in sales from the CDMO business. Sales outside Spain represented 57% of operating revenue in the first half of 2024 compared to 63% in the first half of 2023.

SPECIALTY PHARMACEUTICAL BUSINESS

Sales of the specialty pharmaceutical business

IN € MILLIONS	H1 2024	H1 2023	Growth	% Growth
Prescription-based pharmaceutical products	183.4	184.5	(1.1)	-1%
LMWH franchise	116.9	119.1	(2.1)	-2%
Enoxaparin biosimilar	69.8	74.5	(4.8)	-6%
Bemiparin (Hibor)	47.2	44.5	2.6	6%
Sales in Spain	30.5	31.9	(1.4)	-4%
International sales	16.7	12.6	4.0	32%
Okedi	12.5	5.2	7.3	141%
Neparvis	25.0	22.1	2.8	13%
Volutsa	4.7	8.3	(3.5)	-43%
Vytorin & Orvatez	13.0	13.7	(0.7)	-5%
Other products	18.1	23.9	(5.8)	-24%
Discounts to the National Health System	(6.9)	(7.8)	1.0	-12%
Contrast agents and other hospital products	26.4	23.6	2.8	12%
Other products	0.7	0.5	0.1	26%
Total specialty pharmaceutical business	210.5	208.6	1.9	1%

Sales of **prescription-based pharmaceutical** products decreased 1% to 183.4 million euros in the first half of 2024.

Sales of the **heparin franchise** (Low Molecular Weight Heparins and other heparins) decreased by 2% to 120.7 million euros in the first half of 2024. However, sales of the heparin franchise increased by 14% to 64.3 million euros in the second quarter of 2024 compared to the first quarter of the 2024. Heparin sales represented 37% of operating revenue in the first half of 2024 compared to 32% in the first half of 2023.

Heparin franchise

IN € MILLIONS	H1 2024	H1 2023	Growth	% Growth
LMWH franchise	116.9	119.1	(2.1)	-2%
Enoxaparin biosimilar	69.8	74.5	(4.8)	-6%
Bemiparin (Hibor)	47.2	44.5	2.6	6%
Sales in Spain	30.5	31.9	(1.4)	-4%
International sales	16.7	12.6	4.0	32%
Other heparins ¹	3.7	4.3	(0.6)	-14%
Heparins franchise	120.7	123.4	(2.8)	-2%

LOW MOLECULAR WEIGHT HEPARINS

Sales of **Low Molecular Weight Heparins (LMWH)** (enoxaparin biosimilar and bemiparin) decreased by 2% to 116.9 million euros in the first half of 2024 mostly due to a decrease in enoxaparin sales.

IN € MILLIONS	Q1 2022	Q2 2022	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024
Enoxaparin biosimilar	44.2	37.9	37.1	33.6	34.9	39.6	33.6	39.8	34.6	35.1
Bemiparin (Hibor)	30.0	25.8	20.0	27.9	24.4	20.2	22.8	26.9	19.7	27.5
Sales in Spain	17.5	17.2	15.7	16.5	17.3	14.6	14.2	15.6	15.4	15.1
Intl. sales	12.5	8.6	4.4	11.5	7.1	5.6	8.6	11.4	4.3	12.4
Total LMWH sales	74.2	63.7	57.2	61.6	59.3	59.8	56.3	66.7	54.3	62.6

Sales of the **enoxaparin biosimilar** decreased by 6% to 69.8 million euros in the first half of 2024 mainly due to lower orders from partners in the first half of 2024. However, ROVI expects a greater concentration of orders from partners in the second half of 2024 compared to the first half of the year.

Bemiparin sales increased 6% to 47.2 million euros in the first half of 2024. International sales of bemiparin increased by 32% to 16.7 million euros, mainly linked to higher orders from partners in China, Turkey and Greece. Sales of bemiparin in Spain (Hibor®) showed a decrease of 4% to 30.5 million euros in the first half of 2024 compared to the first half of 2023, mainly due to lower penetration of the product in the prophylaxis segment. Nevertheless, they increased by 3% in the second quarter of 2024 in comparison to the second quarter of 2023. Therefore, ROVI expects full-year sales of bemiparin to increase by a low-single-digit percentage in 2024 compared to 2023.

¹ Other heparins are reported in the "Contrast agents and other hospital products" line.

OTHER PRESCRIPTION-BASED PHARMACEUTICAL PRODUCTS

Sales of **Neparvis®**, a specialty product from Novartis, launched in Spain in December 2016, indicated for the treatment of adult patients with symptomatic chronic heart failure and reduced ejection fraction, increased 13% to 25.0 million euros in the first half of 2024, compared to 22.1 million euros in the first half of 2023.

Sales of **Volutsa®**, a specialty product from Astellas Pharma indicated for the treatment of moderate to severe storage symptoms and voiding symptoms associated with benign prostatic hyperplasia, launched in Spain in February 2015, decreased by 43% to 4.7 million euros in the first half of 2024 mainly due to a product price reduction of 47% in the second quarter of 2023.

Sales of **Vytorin® and Orvatez®**, specialty products from Organon & Co. ("Organon") indicated as adjunctive therapy to diet in patients with hypercholesterolemia, decreased 5% to 13.0 million euros in the first half of 2024, compared to the first half of 2023. This decrease was mostly caused by a deferral of Orvatez® wholesalers' purchases to July. Therefore, Orvatez®'s sales for the year are expected to remain stable in comparison to full year 2023 sales. ROVI ceased to distribute Vytorin® as of 31 January 2023.

Sales of **Okedi®**, the first ROVI product based on its leading-edge drug delivery technology, ISM®, and indicated for the treatment of schizophrenia in adults for whom tolerability and effectiveness has been established with oral risperidone, totalled 12.5 million euros in the first half of 2024. Okedi® sales multiplied the 2023 first-half sales by 141%. In the first half of 2024, it was approved in the United States (under the brand name Risvan®), Canada and Australia; in 2023, it was launched in Portugal, Italy, Austria, Greece and Serbia; and in 2022, it was launched in Germany, UK and Spain.

- In Germany, the product continues to be received very positively in the medical education and dissemination activities carried out by ROVI. It is already present in 83% of targeted hospitals. ROVI's salesforce is currently running a new training project for nurses in order to improve the administration of Okedi® in hospitals and continue to increase the product's sales.
- In Spain, the product is available in 100% of the autonomous communities and is marketed in over 90% of hospitals. Additionally, more than 45% of the psychiatrist contacted by ROVI have experience in the use of the drug. Likewise, the capture of market share in the retail and hospital markets is progressing favourably.
- In Portugal, sales of the product are performing very positively. In the first half of 2024, Okedi® was being marketed in 68% of the hospitals.
- In Italy, access to doctors continues to be very positive. In the first half of 2024, 40% of psychiatrists that were approached, attended education activities carried out by ROVI. Likewise, Okedi® is available in 77% of the main hospitals. Sales are expected to grow and the product may be present in all the main hospitals by the end of 2024.

- In Austria, penetration of the product is being very positive. Okedi® was launched in the fourth quarter of 2023 and, in the first half of 2024, ROVI's salesforce had visited 90% of targeted hospitals.

ROVI ceased to promote and distribute **Xelevia®** (sitagliptin) and **Velmetia®** (sitagliptin and metformin), two antidiabetic drugs from Merck Sharp and Dohme ("MSD"), as of 31 January 2024. Sales of both products were 1.2 million euros in the first half of 2024 compared to 6.1 million euros in the first half of 2023.

CONTRAST AGENTS AND OTHER HOSPITAL PRODUCTS

Sales of **contrast imaging agents and other hospital products** increased by 12% to 26.4 million euros in the first half of 2024.

CDMO BUSINESS

CDMO sales fell by 31% to 118.9 million euros in the first half of 2024 in comparison to the first half of 2023, mainly due to (i) lower revenues from the manufacture of the COVID-19 vaccine in comparison to the first half of 2023, when ROVI had booked higher income related to the production of the "pandemic" COVID-19 vaccine; and, (ii) lower revenues related to the activities carried out to prepare the plant for the production of the vaccine under the agreement with Moderna.

In July 2024, the Investment Accelerator of the Community of Madrid declared the expansion that ROVI, through its subsidiary ROVI Pharma Industrial Services, S.A.U., is undertaking at its plant in San Sebastián de los Reyes to be a strategic project. With this expansion, ROVI will increase its current production capacity in San Sebastián de los Reyes facility to 500 million injectables by 2027. This expansion project aims to position ROVI as one of the world leaders in the production of injectables.

OTHER INCOME

Other income (subsidies) increased by 0.03 million euros to 0.2 million euros in the first half of 2024 compared to the first half of 2023, mainly due to higher subsidies received in the period.

COSTS

GROSS PROFIT

Gross profit decreased 9% to 195.6 million euros in the first half of 2024 compared to the first half of 2023. The gross margin increased from 56.6% in the first half of 2023 to 59.4% in the first six months of 2024, an increase of 2.8 percentage points. This increase was mainly due to: (i) the decrease in the contribution to the manufacturing business (CDMO) of revenue relating to activities to prepare the plant to produce medicines under the agreement with Moderna, which contributed lower margins to Group sales; (ii) the increased contribution to the CDMO business by existing customers (excluding Moderna), which contributed higher margins; and (iii) the increased contribution of sales of Okedi®, which added higher margins.

In the first six months of 2024, raw material prices for low-molecular-weight heparins (LMWH) fell 55% compared to the first half of 2023. ROVI expects this decrease in LMWH raw material prices to be confirmed in 2024. Notwithstanding, in spite of the decrease in LMWH raw material prices, the impact on the gross margin was negative in the first six months of 2024. However, a positive impact on the gross margin is expected from 2025 onwards.

RESEARCH AND DEVELOPMENT EXPENSES

R&D expenses increased 13% to 12.2 million euros in the first half of 2024. They were mainly related to (i) the development of the phase I of Letrozole LEBE and (ii) the development of the phase I of a new formulation of Risperidone ISM® for a 3-monthly injection. Both projects were in the preparation phase in the first half of 2023.

SELLING, GENERAL AND ADMINISTRATIVE EXPENSES

SG&A expenses increased 5% to 113.5 million euros in the first half of 2024 compared to the same period of the previous year. This increase was a consequence of (i) higher "Employee benefit expenses (excl. R&D)", which increased 10% in the first half of 2024 versus the first half of 2023 mainly due to a 10.3% wage increase under the General Collective Agreement for the Chemical Industry, and (ii) an increase in "Other operating expenses (excl. R&D)" due to Okedi®'s launch in Europe.

SG&A expenses

IN € MILLIONS	H1 2024	H1 2023	Growth	% Growth
Employee benefit expenses (excl. R&D)	59.3	54.0	5.3	10%
Other operating expenses (excl. R&D)	54.2	53.8	0.5	1%
Total SG&A expenses	113.5	107.8	5.7	5%

DEPRECIATION

Depreciation and amortisation expenses increased by 13% to 13.4 million euros in the first half of 2024, as a result of the new property, plant and equipment and intangible asset purchases made during the last year.

NET FINANCIAL COST


Net financial cost amounted to 0.3 million euros in the first half of 2024, compared to net financial income of 0.6 million euros in the first half of 2023. This decrease was mainly due to (i) lower financial revenues and (ii) higher financial expenses due to an increase in financial debt (please see page 19 for further detail).

EFFECTIVE TAX RATE

The **effective tax rate** was 21.0% in the first half of 2024 compared to 22.4% in the first half of 2023. This decrease in the effective tax rate was due to (i) a decrease in "Profit before income tax," and (ii) an increase in tax credits derived from research and development expenses compared to the first half of 2023.

FINANCIAL PERFORMANCE

Million euros



⁽¹⁾ Net profit refers to the profit for the period.

⁽²⁾ Gross profit calculated as total revenue less change in inventories of finished goods and work in progress and raw materials and consumables used.

⁽³⁾ SG&A calculated as the amount of employee benefit expenses plus other operating expenses plus work carried out by the Group on non-current assets minus research & development expenses.

⁽⁴⁾ R&D expenses are calculated as the sum of employee benefit expenses and other operating expenses related to scientific research and technological development.

EBITDA

EBITDA totalled 69.9 million euros in the first half of 2024, a decrease of 28% compared to the first half of 2023, reflecting a 4.3 percentage point decrease in the EBITDA margin, which was down to 21.2% in the first half of 2024 from 25.5% in the first half of 2023.

EBIT

EBIT decreased by 34% to 56.5 million euros in the first half of 2024, reflecting a 5.2 percentage point decline in the EBIT margin, which was down to 17.1% in the first half of 2024 from 22.4% in the first half of 2023.

NET PROFIT

Net profit decreased by 33%, from 66.6 million euros in the first half of 2023 to 44.3 million euros in the first half of 2024.

Non-controlling interests refer to ROVI's partners in Glicopepton Biotech, S. L.

PRE-R&D/FLAT R&D

EBITDA “Pre-R&D”, calculated excluding R&D expenses, decreased by 24%, from 107.9 million euros in the first half of 2023 to 82.1 million euros in the first half of 2024, reflecting a 3.4 percentage point decrease in the EBITDA margin to 24.9% in the first half of 2024 (see “Pre-R&D costs” columns of the table below). Likewise, recognising the same amount of R&D expenses in the first half of 2024 as in the first half of 2023, EBITDA would have decreased by 27% to 71.3 million euros, reflecting a 3.8 percentage point decrease in the EBITDA margin to 21.6% in the first half of 2024, down from 25.5% in the first half of 2023 (see “Flat R&D costs” columns of the table below).

EBIT “Pre-R&D”, calculated excluding R&D expenses, decreased by 29%, from 96.0 million euros in the first half of 2023 to 68.6 million euros in the first half of 2024, reflecting a 4.4 percentage point decrease in the EBIT margin to 20.8% in the first half of 2024 (see “Pre-R&D costs” columns of the table below). Likewise, recognising the same amount of R&D expenses in the first half of 2024 as in the first half of 2023, EBIT would have decreased by 32% to 57.8 million euros, reflecting a 4.8 percentage point decline in the EBIT margin to 17.6% in the first half of 2024, down from 22.4% in the first half of 2023 (see “Flat R&D costs” columns of the table below).

Net profit “Pre-R&D”, calculated excluding R&D expenses, decreased by 28%, from 75.0 million euros in the first half of 2023 to 54.0 million euros in the first half of 2024 (see “Pre-R&D costs” columns of the table below). Likewise, recognising the same amount of R&D expenses in the first half of 2024 as in the first half of 2023, net profit would have decreased by 32% to 45.4 million euros (see “Flat R&D costs” columns of the table below) in the first half of 2024.

Pre-R&D/Flat R&D

IN € MILLIONS	Reported		Pre-R&D costs			Flat R&D costs		
	H1 2024	H1 2023	H1 2024	H1 2023	% Growth	H1 2024	H1 2023	% Growth
Operating revenue(1)	329.3	380.8	329.3	380.8	-14%	329.3	380.8	-14%
Other income(2)	0.2	0.2	0.2	0.2	19%	0.2	0.2	19%
Total revenue(3)	329.5	381.0	329.5	381.0	-14%	329.5	381.0	-14%
Cost of sales(4)	(133.9)	(165.3)	(133.9)	(165.3)	-19%	(133.9)	(165.3)	-19%
Gross profit(5)	195.6	215.7	195.6	215.7	-9%	195.6	215.7	-9%
% margin(11)	59.4%	56.6%	59.4%	56.6%	2.8 pp	59.4%	56.6%	2.8 pp
R&D expenses(6)	(12.2)	(10.8)	0.0	0.0	n.a.	(10.8)	(10.8)	n.a.
SG&A(7)	(113.5)	(107.8)	(113.5)	(107.8)	5%	(113.5)	(107.8)	5%
Share of profit in associates and joint ventures	(0.02)	(0.01)	(0.02)	(0.01)	69%	(0.02)	(0.01)	69%
EBITDA(8)	69.9	97.1	82.1	107.9	-24%	71.3	97.1	-27%
% margin(11)	21.2%	25.5%	24.9%	28.3%	-3.4 pp	21.6%	25.5%	-3.8 pp
EBIT(9)	56.5	85.2	68.6	96.0	-29%	57.8	85.2	-32%
% margin(11)	17.1%	22.4%	20.8%	25.2%	-4.4 pp	17.6%	22.4%	-4.8 pp
Net profit(10)	44.3	66.6	54.0	75.0	-28%	45.4	66.6	-32%
% margin(11)	13.5%	17.5%	16.4%	19.7%	-3.3 pp	13.8%	17.5%	-3.7 pp

(1) Operating revenue refers to revenue.

(2) Other income includes the recognition of government grants on non-financial non-current assets and other.

(3) Total revenue calculated as revenue plus the recognition of government grants on non-financial non-current assets and other.

(4) Cost of sales calculated as the amount of procurements plus that corresponding to the change in inventories of finished goods and work in progress and raw materials and consumables use.

(5) Gross profit calculated as revenue plus the recognition of government grants on non-financial non-current assets and other less change in inventories of finished goods and work in progress and raw materials and consumables used.

(6) R&D expenses are calculated as the sum of employee benefit expenses and other operating expenses related to scientific research and technological development.

(7) SG&A calculated as the amount of employee benefit expenses plus other operating expenses plus work carried out by the Group on non-current assets minus research & development expenses.

(8) EBITDA calculated as profit before interest, taxes, depreciation and amortization.

(9) EBIT calculated as profit before taxes and interest.

(10) Net profit refers to profit for the period.

(11) The gross margin and the EBITDA, EBIT and net profit margins are calculated as the result of dividing the gross profit, the EBITDA, the EBIT and the net profit, respectively, by revenue, expressed as a percentage.

DIVIDEND

ROVI's General Shareholders Meeting, held on 24 June 2024, approved the payment of a gross dividend of 1.1037 per share. This represents approximately 35% of the 2023 consolidated net profit attributed to the parent company, broken down as follows:

- Application of profit: the entire profit of Laboratorios Farmacéuticos ROVI, S.A. for 2023, 12,071,013.68 euros, was applied to the dividend distribution; and
- Additionally, a further 47,546,618.80 euros was distributed as dividends charged to the freely-available reserves accounted for as "Retained earnings".

This dividend was paid on 10 July 2024.

FINANCIAL POSITION

Balance Sheet

IN € MILLIONS	June 30, 2024	Dec 31, 2023	Growth	% Growth
Assets				
Non-current assets	316.5	290.6	26.0	9%
Current assets	540.8	509.3	31.4	6%
Total assets	857.3	799.9	57.4	7%
Equity	482.8	543.5	(60.7)	-11%
Liabilities				
Non-current liabilities	102.1	56.5	45.6	81%
Financial debt	98.1	52.2	45.9	88%
Current liabilities	272.5	199.8	72.6	36%
Financial debt	23.0	13.2	9.8	75%
Total liabilities	374.6	256.4	118.2	46%
Total equity and liabilities	857.3	799.9	57.4	7%

TOTAL ASSETS

ROVI's **total assets** increased by 7%, from 799.9 million euros as of December 31, 2023 to 857.3 million euros as of June 30, 2024, mainly because of (i) an increase of 19.3 million euros in "Cash and cash equivalents"; (ii) an increase of 17.5 million euros in "Inventories", mostly due to an increase in heparin and risperidone stocks; and (iii) an increase of 19.1 million euros in "Investments in joint ventures and associates", mainly related to the cash contribution of 18.8 million euros that ROVI will be making to Terafront Farmatech, which has not yet been charged to profit and loss.

EQUITY

ROVI's **equity** decreased by 60.7 million euros to 482.8 million euros as of June 30, 2024. This decrease resulted from the share Buy-Back Programme executed in the first half of 2024.

TOTAL LIABILITIES

ROVI's total **liabilities** increased by 46% from 256.4 million euros as of December 31, 2023 to 374.6 million euros as of June 30, 2024, mainly due to (i) an increase of 49.3 million euros in the "Trade and other payables" caption which includes 18.8 million euros that ROVI will be making to Terafront Farmatech and recognition of a dividend of €59.6 million euros, which had yet to be paid as of 30 June 2024; and (ii) an increase of 45.9 million euros in the "Financial debt" item.

As of June 30, 2024, ROVI **total debt** increased to 121.2 million euros. Debt with public administration, which is 0% interest rate debt, represented 8% of total debt as of June 30, 2024.

Total Debt

IN € THOUSANDS	June 30, 2024	Dec 31, 2023	Interest rate
Bank borrowings	94,609	37,745	0.68-4.73
Debt with public administration	9,095	8,890	0
Financial liabilities for leases	17,455	18,792	-
Total	121,159	65,427	

As of June 30, 2024, bank borrowings increased by 56.9 million euros. In December 2017, ROVI announced the European Investment Bank (EIB) had granted it a loan to support its investments in Research, Development and Innovation. The loan was for 45 million euros. As of June 30, 2024, ROVI had drawn 45 million euros against this credit line; 5 million euros at a variable interest rate of Euribor at 3 months + 0.844% (the latest interest rate paid was 4.729% in July 2024) and 40 million euros at a fixed interest of 0.681%. Repayment of the variable interest loan started in October 2021 (quarterly repayments) and its current outstanding balance is 3 million euros. Likewise, repayment of the fixed interest loan started in February 2023 (quarterly repayments) and its current outstanding balance is 31.4 million euros. The credit at a variable interest matures in 2028 and the credit at a fixed interest matures in 2029, both includes a grace period of 3 years.

In July 2022, ROVI announced that the European Investment Bank (EIB) had granted it a new loan to support its investments in Research, Development and Innovation. The loan is for 50 million euros with a repayment period of 10 years, has a three-year grace period, and may be drawn down over a term of two years. As of June 30, 2024, ROVI had drawn 10 million euros against this new credit at a variable rate of Euribor at 3 months + 0.655% (the interest rate for the first repayment is 4.552%).

Additionally, ROVI has signed three credit policies: one in September 2023 for 20 million euros and another in March 2024 for 20 million euros, both with conditions of Euribor 3 months + 0.50%. In June 2024, a third policy was signed, also for 20 million euros, at Euribor 3 months + 0.65%, as well as two loans of 25 million euros each at fixed rates of 3% and 3.49%, respectively. As of 30 June 2024, ROVI had not drawn down on any of the policies.

GROSS CASH POSITION AND NET DEBT


As of June 30, 2024, ROVI had a **gross cash position** of 46.4 million euros, compared to 26.8 million euros as of December 31, 2023, and **net debt** of 74.7 million euros, compared to 38.6 million euros as of December 31, 2023.

Gross cash position and net debt

IN € MILLIONS	June 30, 2024	Dec 31, 2023
Equity securities	—	0.0
Deposits	1.9	1.4
Cash and cash equivalents	44.6	25.3
Gross cash position	46.4	26.8
Financial debt	(121.2)	(65.4)
(Net debt)/Net cash	(74.7)	(38.6)

Net cash generated in operating activities amounted to 29.7 million euros in the first half of 2024, compared to 52.5 million euros in the same period of 2023. Net cash generated from operating activities excluding changes in working capital decreased 22% to 49.1 million euros in the first half of 2024 from 62.7 million euros in the same period of 2023.

Million euros



(1) Net cash/Net debt is composed of equity securities, plus deposits, plus financial derivatives, plus financial assets at amortised cost, plus cash and cash equivalents, less current and non-current financial debt.

LIQUIDITY

Cash Flow

IN € MILLIONS	H1 2024	H1 2023	Growth	% Growth
Cash flow from operating activities	29.7	52.5	(22.8)	-43%
Cash flow from investing activities	(18.7)	(17.4)	(1.3)	8%
Cash flow from financing activities	8.2	(6.3)	14.5	n.a
Net increase/ (decrease) in cash	19.3	28.9	(9.6)	-33%
Cash at the beginning of the period	25.3	124.9	(99.6)	-80%
Cash at the end of the period	44.6	153.8	(109.2)	-71%

CASH FLOW FROM OPERATING ACTIVITIES

Cash flow from operating activities decreased to 29.7 million euros in the first half of 2024 from 52.5 million euros in the same period of 2023. This decrease was mainly due to:

- the decrease of 29.7 million euros in "Profit before income tax";
- the increase of 27.0 million euros in the "Trade and other receivables" item in the first half of 2024, compared to an increase of 54.2 million euros in the first half of 2023; and
- the decrease of 29.0 million euros in the "Trade and other payables" item in the first half of 2024, compared to a decrease of 21.6 million euros in the first half of 2023.

These negative impacts were partially offset by:

- the decrease of 16.1 million euros in the "Inventory" item in the first half of 2024 compared to a decrease of 40.1 million euros in the first half of 2023; and
- the booking of (13.9) million euros under the "Cash flow from contract manufacturing services" caption in the first half of 2024 relating to the allocation of more revenue to the income statement than payments received, compared to the (23.3) million euros recognized in the first half of 2023.

CASH FLOW FROM INVESTING ACTIVITIES

ROVI invested 18.7 million euros in the first half 2024, compared to 18.2 million euros in the first half of 2023.

Purchases of property, plant and equipment and intangible assets ("Capex")

IN € MILLIONS	H1 2024	H1 2023	Growth	% Growth
Madrid Injectable plant	0.2	0.4	(0.2)	-47%
San Sebastián de los Reyes plant	1.1	0.5	0.6	138%
Granada plant	0.3	0.3	0.0	-7%
Alcalá de Henares plant	0.5	0.5	0.0	9%
Escúzar plant ⁽¹⁾	0.4	3.3	(2.8)	-86%
Expenditure on maintenance and other capex	0.8	0.8	0.0	4%
Maintenance Capex	3.4	5.7	(2.3)	-40%
ISM industrialisation	1.3	2.9	(1.5)	-53%
Glicopepton	1.9	0.3	1.5	n.a
New filling lines and operations expansion	12.0	9.2	2.8	31%
Investment Capex	15.2	12.4	2.8	23%
Total Capex	18.7	18.2	0.5	3%

(1) In the first half 2023 press release, this figure was reported as Investment Capex.

FREE CASH FLOW

Free cash flow decreased to 11.2 million euros in the first half of 2024 from 35.1 million euros in the first half of 2023.

Free cash flow

IN € MILLIONS	H1 2024	H1 2023
Net cash generated from (used in) operating activities	29.7	52.5
Purchases of intangible assets	(0.6)	(0.2)
Purchases of property, plant and equipment	(18.0)	(18.0)
Proceeds from sale of property, plant and equipment	0.0	0.0
Interest received	0.1	0.8
Free cash flow	11.2	35.1

CASH FLOW FROM FINANCING ACTIVITIES

Cash flow from financing activities was 8.2 million euros in the first half of 2024 versus (6.3) million euros in the first half of 2023. This increase was mainly attributable to an increase in "Proceeds from financial debt" of 70.2 million euros in the first half of 2024 in comparison to 0.7 million euros in the first half of 2023.



Javier López-Belmote Encina, Deputy Chairman and Chief Financial Officer of ROVI, said: *"2024 is emerging as a year of transition, a year in which value is created for the future. In this context, in the first half of the year, operating revenue was 329.3 million euros, and gross margin increased by 2.8 percentage points to 59.4%. Likewise, we expect a further improvement in said margin from 2025 onwards assuming an expected decline in raw material prices for low-molecular-weight heparins. In addition, operating expenses (excluding R&D expenses and employee benefit expenses) slightly increased compared to the first half of 2023 as a result of an efficient cost containment policy in the first half of the year. We are very satisfied with the execution of the Share Buy-Back Programme, which concluded successfully*

in the terms stipulated. ROVI's commitment to innovation is reflected in the figures for the first six months of 2024. We are in a new growth phase and hope that the strength of our balance sheet will allow us to take further opportunities to expand our sales and increase the return on our asset".

OUTLOOK

For 2024, ROVI expects its operating revenue to **decrease by a mid-single-digit percentage** in comparison with 2023. Notwithstanding, there are certain factors that have been considered when calculating this guidance that, although they could be relevant to the estimates, are difficult to specify at present, including, among others:

1. First, the saturation of the National Health Systems due to the low vaccination ratios during the 2023 COVID-19 campaign could favour a more successful vaccination campaign in 2024. However, as of today's date, the Company is not in a position to forecast how demand and production might evolve for the remainder of the vaccination campaign in 2024.
2. Second, it is hoped that the expansion of the compounding, aseptic filling, inspection, labelling and packaging capacities at ROVI's facilities in Madrid and the current high demand for CDMO services in the market might favour obtaining new business, with the resulting sales impact. This would have to be taken into consideration but cannot be estimated at present.

R&D UPDATE

ISM® technology platform

Okedi® (Risperidone ISM®) is the first ROVI product based in its leading-edge drug delivery technology, ISM®. It is a novel investigational antipsychotic for the treatment of schizophrenia with once-monthly (every 28 days) injections which has been developed and patented by Laboratorios Farmacéuticos ROVI S.A. and which, as of the first injection, provides immediate and sustained plasmatic drug levels and does not require loading doses or supplementation with oral risperidone.

On 15 February 2022, the European Commission authorised the marketing of Okedi® (Risperidone ISM®) for the treatment of schizophrenia in adults for whom tolerability and effectiveness has been established with oral risperidone, and it was launched in 2022 in Germany, UK and Spain and in 2023 in Portugal, Italy, Austria, Greece and Serbia.

On 21 March 2024, ROVI received authorisation from Health Canada for the marketing of Okedi® (Risperidone ISM®) for the treatment of schizophrenia in adults throughout Canada. ROVI has likewise obtained approval in Australia.

On 29 March 2024, ROVI reported that the United States Food and Drug Administration (FDA) had authorised the marketing of Risvan® (Risperidone ISM®) for the treatment of schizophrenia in adults. Additionally, following normal practice, the FDA has required that, as a post-marketing commitment, a pharmacokinetic study be conducted to evaluate exposure to Risvan® approximately equivalent to the daily administration of 6 mg of oral risperidone. The clinical protocol for the study will be reviewed and agreed previously with the FDA and the final report on the clinical study will be submitted by July 2026. This additional study does not affect approval or commercialization.

Likewise, ROVI's R&D team is progressing in the development of a new formulation of Risperidone for a 3-monthly injection, which would complement the current 4-weekly formulation of Risperidone ISM® for the maintenance treatment of adult patients with clinically stable schizophrenia. The Company is currently conducting a phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics of various candidate formulations at different dose strengths and injection sites; patient's recruitment for this study began in September of 2023.

Lastly, the Company decided to commence the clinical development of a new three-monthly formulation of Letrozole (hereinafter, Letrozole LEBE), rather than the initially planned annual formulation of Letrozole ISM®. The objective of this new development is to reach bioequivalence in the plasma levels of letrozole in comparison with the daily administration of oral doses of Femara® 2.5 mg.

With this new clinical programme for Letrozole LEBE, ROVI estimates it could reduce the research times in comparison to those for an annual formulation of the product, thus making it likely that the three-monthly formulation could be marketed several years earlier and, furthermore, the investment necessary to attain the objectives of this project could also be reduced.

Accordingly, ROVI is currently carrying out a phase I clinical trial in Europe to evaluate the pharmacokinetics, safety and tolerability of single ascending doses of Letrozole LEBE, at different strengths, in voluntary healthy post-menopausal women (LEILA-1 study). This first clinical trial of Letrozole LEBE began in July 2023.

ESG

For the second year running, ROVI has obtained the best ranking in the pharmaceutical industry category in the world rating of environmental, social and corporate governance (ESG) risks drawn up by Sustainalytics, a leading independent ESG research, rating and analytics firm that supports investors around the world with the development and implementation of responsible investment strategies. ROVI has revalidated its first place among 431 companies rated in the pharmaceutical industry group and remains in 22nd place among a total of 895 companies rated in the entire sector, which includes "biotechnology companies, pharmaceutical laboratories and laboratory equipment companies."

In the rating process carried out in July 2023, Sustainalytics has analysed the Company's performance in sustainability aspects considered material in the pharmaceutical sector, highlighting ROVI's sound management of ESG risks related to product quality and safety, corporate governance, business ethics, human capital, the fight against climate change and anti-corruption and anti-bribery practices. ROVI has obtained a higher than-average score in areas such as the board's involvement in the Company's environmental and social aspects, implementation of the environmental policy and a sound quality and safety programme for products and services, as well as the integration of ethical practices into all tiers of the organisation.

Commitment to sustainability

In 2022, ROVI approved its ESG Master Plan 2023-2025, a document that sets out 19 strategic ESG goals. With a three-year horizon, the Group has established a roadmap for attaining the Sustainable Development Goals (SDGs) of the United Nations Agenda 2030, with which ROVI, as a member of the Global Compact, is aligned.

The Group focuses its action on five priority areas:

- Becoming a leader in governance committed to sustainability.
- Commitment to sustainable management to combat the global environmental challenges: fight against climate change, promotion of the circular economy and efficient water management.
- Positioning itself as a key player in caring for persons and integrating specialised and diverse talent.
- Promoting responsible management of the supply chain, ensuring ethical and environmental standards in each one of its links.
- Promoting R&D&I activities by establishing partnerships with key players.

In addition, ROVI, as a member of the United Nations Global Compact, upholds, by adopting and disseminating it, the inclusion of the principles of this Compact, as well as other international instruments, especially in the spheres of human rights, workplace practices, the environment and the fight against corruption.

KEY OPERATING AND FINANCIAL EVENTS

ROVI provides information and guidance on its strategic plan for expansion and growth

ROVI informed (by publication of the inside information number 2290 dated 24th of June 2024) that the Company expects that, given its differential characteristics, Risperidone ISM® will reach potential sales of between 200 and 300 million euros globally in upcoming years and will become a significant player worldwide in the field of long-acting injectables to treat schizophrenia.

ROVI has likewise informed that in June 2024, the Group obtained the European authorities' approval for the commencement of commercial activity at its new sodium heparin plant in Escúzar (Granada). Thus, ROVI is positioned as one of the largest pharmaceutical industrial groups in Spain, with eight fully-integrated plants and a ninth under construction.

The Group has five plants to manufacture its own products and three for contract manufacturing. In Andalusia, it has three plants for its own manufacturing: two

engaged in producing the active substance of low-molecular-weight heparins, in Granada and Escúzar, and the new plant that will be producing sodium heparin. ROVI is, therefore, prepared for production of a medicine like sodium heparin, which is classified as essential by the World Health Organisation and is, moreover, among the medicines included in the European Union's Critical Medicine Alliance, in which ROVI participates.

Additionally, ROVI has two plants in Madrid engaged in the production of medicines based on its ISM® technology, in which 35.6 million euros has been invested in the last five years: at the first plant, the Company produces Risperidone ISM®, while the second is used to manufacture products under development that use highly potent active ingredients.

Furthermore, ROVI has three plants engaged in contract manufacturing: in particular, two injectables manufacturing plants, located in San Sebastián de los Reyes and Madrid, and a third in Alcalá de Henares, which is engaged in producing solid oral forms and is a packaging centre of excellence.

Likewise, ROVI remains committed to the vertical integration of its value chain in order to achieve strategic autonomy in its medicine manufacturing process. In this respect, ROVI is making significant investments in the construction of a new plant in Huesca, which will transform pig mucosa into crude heparin and is considered likely to come into operation in 2026.

ROVI's Share Buy-Back Programme

ROVI informed (by publication of the inside information number 1926 dated 26th of July 2023) that the Company launched, effective as of 26 July, 2023, a share buy-back programme (the "Buy-Back Programme"), in accordance with the following terms:

1. **Purpose and scope:** the Buy-back Program's purpose is to redeem own shares of ROVI (share capital reduction) and, at the same time, boost the remuneration of the ROVI shareholder by increasing the profit per share.
2. **Term:** from 26 July 2023, and for a period of 12 months.
3. **Maximum monetary amount:** up to 130,000,000 euros, provided that the maximum price per share may not exceed that provided for by article 3.2 of Delegated Regulation 2016/1052.

The authorization granted by the general shareholders' meeting of the Company on 17 June 2021 established (a) a minimum price for the acquisition corresponding to the nominal value of the acquired shares and (b) a maximum price for the acquisition corresponding to a price not above the highest between (i) the last transaction carried out on the market by independent parties and (ii) the highest price of a purchase order amongst those contained in the orders book.

4. **Maximum number of shares to be acquired:** 2,700,000 shares of the Company, representing approximately 5% of the Company's share capital on 26 July 2023.

5. **Trading volume to be considered as reference:** the trading volume to be taken as a reference for the purposes of the provisions of article 3.3 of Delegated Regulation 2016/1052 for the entire duration of the buy-back program shall be 25% of the average daily volume of ROVI's shares on the trading venue on which the purchase is carried out during the twenty trading days prior to the date of the purchase.

On 11 June 2024, ROVI concluded the Buy-Back programme, having acquired 2,233,466 shares for an amount of 130.0 million euros, representing approximately 4.3% of the share capital.

As notified when the Buy-Back Programme commenced, the purpose of the Programme was to cancel shares of ROVI through a reduction of capital and, at the same time, to contribute to ROVI's shareholder remuneration by increasing the profit per share. The reduction of the capital will be carried out by cancelling 2,780,395 shares. The latter corresponds to (i) the shares repurchased within the framework of the aforementioned Buy-Back Programme, and (ii) part of the existing treasury shares, which total 546,929. The capital reduction was approved at the Ordinary General Shareholders' Meeting, held on 24 June 2024. The new amount of the share capital, after the shares mentioned have been cancelled and excluded from trading, will appear in the registers of the National Securities Market Commission and Iberclear a few days after registration of the deed of capital reduction. The Company will provide further information in due course.

Finally, after completion of the Buy-back Programme, ROVI informed of the resumption, as of 12 June 2024, of transactions under the liquidity contract signed between the Company and Bestinver, S.V., S.A. for management of the Company's treasury shares, of which the market was informed on 5 April 2022 in the pertinent announcement of other relevant information (register number 15427). When the Buy-Back Programme commenced, the liquidity contract was suspended for the duration of the Programme, in accordance with CNMV Circular 1/2017 of 26 April, Provision Five, 2.c). Likewise, the Company and Bestinver, S.V., S.A. decided to modify the balances of securities and cash associated to the Liquidity Contract in the terms reported to the market as other relevant information on the same date.

ROVI announces agreement to manufacture pre-filled syringes

Laboratorios Farmacéuticos Rovi, S.A. (hereinafter, "ROVI"), informed (by publication of the inside information number 2207 dated 25th April 2024) that its subsidiary, ROVI's wholly owned CDMO platform, ROVI Pharma Industrial Services, S.A.U. (hereinafter "ROIS") had entered into an agreement to support the manufacture of pre-filled syringes for a global pharmaceutical company.

Under the terms of the agreement, ROIS will provide a high-speed production line at the ROIS' San Sebastián de los Reyes facility in Madrid, with an estimated annual capacity of 100 million units. The agreement includes the technology transfer for aseptic filling and has a commercial production term of five years subject to the terms of the agreement, beginning on the date of manufacture of the first commercial lot. After the

technology transfer and regulatory approval, commercial production is expected to commence in 2026. As from 2027, which is expected to be the first full recurrent manufacturing year, the ROVI's Group CDMO division expects to have a positive revenues increase impact ranging between 20% and 45% over 2023 sales.

ROIS is well-equipped to support the production of pre-filled syringes given its deep expertise in the current good manufacturing practice (cGMP) production of sterile injectable products across both vials and pre-filled syringes.

Juan López-Belmonte Encina, Chairman and Chief Executive Officer of ROVI, said: *"We are delighted to be able to support in the manufacture of medicine that is able to prolong the life of millions of people. Our proven experience in the manufacture of high-valued-added injectables and the expansion of our production capacities have positioned us to help meet the rapidly growing demand, which requires a high degree of technological capability."*

ROVI receives the FDA's approval of Risvan® as a treatment for schizophrenia

ROVI informed (by publication of the other relevant information number 27772 dated 2nd April 2024) that the U.S. Food and Drug Administration (FDA) had authorised the marketing of Risvan® (Risperidone ISM®) for the treatment of schizophrenia in adults.

Risperidone ISM® is a prolonged-release injectable antipsychotic developed and patented by ROVI for the treatment of schizophrenia in adults, which, as of the first injection, provides immediate and sustained plasmatic drug levels and does not require loading doses or supplementation with oral risperidone.

This approval is based on the positive results of the pivotal PRISMA-3 study on the efficacy and safety of Risperidone ISM® in schizophrenia patients⁽²⁾. The results obtained in this study show that the two different doses (75 mg and 100 mg once a month) have achieved the prespecified primary and secondary efficacy endpoints for treatment of patients with moderate to severe symptoms of schizophrenia. The primary efficacy endpoint, the PANSS⁽³⁾ total score (mean difference, CI: 95%), improved significantly with Risperidone ISM® 75 mg and 100 mg from the beginning until day 85, with adjusted differences of -13.0 (-17.3 to -8.8; p <0.0001) and -13.3 (-17.6 to -8.9; p<0.0001), respectively, in comparison with the placebo. Significantly improved mean changes for the secondary endpoint, the CGI-S⁽⁴⁾ score, were also obtained for Risperidone ISM® in comparison with the placebo, -0.7 (-1.0 to -0.5; p<0.0001), for both doses, from the beginning until day 85. The significant statistical improvement for both efficacy results was observed as early as 8 days after the first injection. The most frequently reported treatment-emergent adverse events were increased blood prolactin (7.8%), headaches

2 Correll, C.U., Litman, R.E., Filts, Y. et al. Efficacy and safety of once-monthly Risperidone ISM® in schizophrenic patients with an acute exacerbation. *npj Schizophr* 6, 37 (2020). <https://doi.org/10.1038/s41537-020-00127-y>

3 Positive and Negative Syndrome Scale: the Positive and Negative Syndrome Scale is a medical scale based on a semi-structured interview that rates the severity of the symptoms of schizophrenia patients in three domains: positive symptoms, negative symptoms and general psychopathology symptoms.

4 Clinical Global Impression-Severity scale: la escala de Impresión Clínica Global-Gravedad rates the severity of schizophrenia through a question put to the doctor: "Considering your total clinical experience with this particular population, how mentally ill is the patient at this time?"

(7.3%), hyperprolactinemia (5%) and weight increase (4.8%). No important new or unexpected safety information was reported. Likewise, patients who successfully completed the double-blind period were offered the opportunity to continue in a long-term, open-label 12-month extension phase with once every four weeks injections of Risperidone ISM® (75 mg or 100 mg). New, clinically stable patients ("de novo" patients) were also able to enter this open phase of the study. Long-term treatment was observed to be effective, safe and well tolerated in adult patients with schizophrenia, regardless the initial severity of the disease or whether they had been treated previously with Risperidone ISM® during an acute exacerbation or switched from stable doses of oral risperidone⁽⁵⁾. Likewise, Risperidone ISM® provided a swift and sustained improvement in functioning (both social and personal) and health-related quality of life. These findings, together with a quick onset of effectiveness, could help strengthen the therapeutic alliance and possibly lead to an earlier hospital discharge. Furthermore, the patient's functioning either continued to improve or remained stable with long-term treatment⁽⁶⁾.

"We are very excited about the FDA's approval of Risvan® because we think our medicine will be able to contribute to the clinical management of schizophrenia patients, helping to improve treatment adherence", commented Juan López-Belmonte Encina, ROVI's Chairman and Chief Executive Officer.

ROVI, Insud Pharma and Invierte (CDTI) create a company for the research and development of advanced therapies

ROVI informed (by publication of the other relevant information number 27397 dated 12th March 2024) of the agreement that has been concluded with Insud Pharma S.L. and Invierte Economía Sostenible SICCC, SME, S.A. (investment company of Centro para el Desarrollo Tecnológico Industrial EPE – CDTI) to incorporate, together with these two entities, a limited company (Sociedad de responsabilidad limitada) engaged in the research and development of advanced therapies.

This agreement, which was approved at the meeting of the Council of Ministers held on 12 March 2024, falls within the framework of the Vanguard Health Strategic Project for Economic Recovery and Transformation (PERTE), promoted by the Spanish Government. This PERTE concerns the creation of a public-private investment vehicle to develop advanced, innovative and/or emerging medicines, therapies and/or technologies. The goal is to favour the deployment of the technical and industrial capacities necessary to generate a high performance healthcare system intended to protect health by providing an immediate and flexible response to healthcare challenges and favouring sustainability.

The share capital of this new entity will be 49% held by the Ministry of Science, Innovation and Universities through the company Invierte, while Insud Pharma and

5 Filts Y, Litman RE, Martínez J, Anta L, Naber D, Correll CU. Long-term efficacy and safety of once-monthly Risperidone ISM® in the treatment of schizophrenia: Results from a 12-month open-label extension study. *Schizophr Res.* 2021 Nov 27;239:83-91.

6 Litman R, Naber D, Anta L, Martínez J, Filts Y, Correll CU. Personal and Social Functioning and Health-Related Quality of Life in patients with Schizophrenia Treated with the Long-Acting Injectable Antipsychotic Risperidone ISM. *Neuropsychiatr Dis Treat.* 2023 Jan 25;19:219-232.

ROVI will hold 25.5% each. The shareholders undertake to make an initial combined contribution of 74,867,346.94 euros. The investment will be made in accordance with the needs of the projects defined in the future and will be subject to the shareholders' approval of the relevant business plan. Such investment could reach 220 million euros, which would be contributed by the public and private investors that are participating.

It is planned that Innvierte's contributions could be made with European "Next Generation EU" funds, which include the EU Recovery and Resilience Facility established in Regulation (EU) 2921/241 of the European Parliament and of the Council of 12 February 2021.

Juan López-Belmonte, Chairman and CEO of ROVI, highlights the fact that this agreement *"represents an opportunity to help place Spain in a leading position in the clinical research of new therapies, with the capacity to translate this research into manufacturing and thus improve the availability of new therapies to patients. At ROVI, we are delighted to place our knowledge and experience at the service of this great public-private alliance that reinforces our commitment to innovation"*.

About ROVI

ROVI is a pan-European pharmaceutical company specializing and engaging in the research, development, contract manufacturing and marketing of small molecules and biological specialties. The company, in a continuous international expansion process, has subsidiaries in Portugal, Germany, the United Kingdom, Italy, France and Poland and has a diversified marketing portfolio of more than 40 products, among which its flagship product, Bemiparin, already present in more than 60 countries all over the world, should be highlighted. Likewise, in 2017, ROVI commenced the marketing of its Enoxaparin biosimilar, developed in-house, in Europe and it is already marketed in 40 countries. ROVI continues to develop the ISM® Platform technology, a leading-edge line of research in the field of prolonged drug release with proven advantages. For more information, please visit www.rovi.es.

For further enquiries, please contact:

Juan López-Belmonte Encina
Chairman and Chief Executive Officer
www.rovi.es

Javier López-Belmonte Encina
Deputy Chairman and Chief Financial Officer
www.rovi.es

Marta Campos Martínez
Head of Finance
+34 912444422
mcampos@rovi.es
www.rovi.es

Beatriz de Zavala Mazarredo
Investor Relations Analyst
+34 610 737 703
bdezavala@rovi.es
www.rovi.es

Victoria López-Belmonte
Investor Relations Analyst
+34 680 669 485
vlopez-belmonte@rovi.es
www.rovi.es

Forward-looking statements

This news release contains forward-looking statements. Such forward looking statements involve known and unknown risks, uncertainties and other factors which might cause the actual results, financial condition, performance, or achievements of ROVI or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward looking statements. The statements in this press release represent ROVI's expectations and beliefs as of the date of this press release. ROVI anticipates that subsequent events and developments may cause these expectations and beliefs to change. However, while ROVI may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing ROVI's expectations or beliefs as of any date after the date of this press release.

APPENDIX 1

LABORATORIOS FARMACÉUTICOS ROVI, S.A. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS AS OF JUNE 30, 2024 AND DECEMBER 31, 2023

IN € THOUSANDS*	June 30, 2024	Dec 31, 2023
ASSETS		
Non-current assets		
Property Plant and Equipment	261,214	253,652
Intangible assets	33,032	33,902
Investment in joint ventures and associated companies	19,636	567
Deferred income tax assets	2,597	2,343
Equity securities	—	24
Financial receivables	65	65
	316,544	290,553
Current assets		
Inventories	355,486	337,968
Trade and other receivables	136,603	143,314
Current income tax assets	35	—
Prepaid expenses	4,079	2,727
Cash and cash equivalents	44,578	25,322
	540,781	509,331
Total assets	857,325	799,884

* There has been a limited review of the figures for the first half of 2024 by the auditor. The figures as of December 31, 2023 are audited figures.

LABORATORIOS FARMACÉUTICOS ROVI, S.A. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS AS OF JUNE 30, 2024 AND DECEMBER 31, 2023

IN € THOUSANDS*	June 30, 2024	Dec 31, 2023
EQUITY		
Capital and reserves attributed to shareholders of the company	476,092	539,387
Share capital	3,241	3,241
Share premium	87,636	87,636
Legal reserve	673	673
Treasury shares	(157,752)	(107,676)
Retained earnings and voluntary reserves	497,978	385,199
Profit for the period	44,345	170,335
Other reserves	(29)	(21)
Non-controlling interests	6,670	4,107
Total equity	482,762	543,494
LIABILITIES		
Non-current liabilities		
Financial debt	98,144	52,242
Deferred income tax liabilities	944	1,515
Contract liabilities	1,881	1,431
Deferred income	1,139	1,359
	102,108	56,547
Current liabilities		
Financial debt	23,015	13,185
Trade and other payables	191,172	141,895
Current tax liabilities	12,369	5,255
Contract liabilities	45,446	39,044
Deferred income	453	464
	272,455	199,843
Total liabilities	374,563	256,390
Total equity and liabilities	857,325	799,884

* There has been a limited review of the figures for the first half of 2024 by the auditor. The figures as of December 31, 2023 are audited figures.

LABORATORIOS FARMACÉUTICOS ROVI, S.A. AND SUBSIDIARIES
CONSOLIDATED CASH FLOW STATEMENTS FOR THE SIX-MONTH PERIODS ENDING
JUNE 30, 2024 AND JUNE 30, 2023

IN € THOUSANDS*	H1 2024	H1 2023
Revenue	329,336	380,845
Changes in inventories of finished goods and work in progress	71,362	19,171
Raw materials and consumables used	(205,275)	(184,514)
Employee benefit expenses	(64,871)	(59,096)
Other operating expenses	(61,394)	(61,466)
Work carried out by the Group on non-current assets	562	1,960
Amortisation and depreciation	(13,446)	(11,865)
Recognition of government grants on non-financial non-current assets and other	204	172
Share of profit in joint ventures and associated companies	(22)	(13)
OPERATING PROFIT (EBIT)	56,456	85,194
Finance income	100	766
Finance costs	(644)	(366)
Impairment and gain or loss on measurement of financial instruments	67	72
Exchange difference	163	166
FINANCE INCOME/(COSTS) - NET	(314)	638
PROFIT BEFORE INCOME TAX	56,142	85,832
Income tax	(11,804)	(19,188)
PROFIT FOR THE PERIOD	44,338	66,644
Profit for the period attributable to parent company	44,345	66,646
Profit attributable to minority interests	7	2

*There has been a limited review of the figures for the first half of 2024 and 2023 by the auditor.

LABORATORIOS FARMACÉUTICOS ROVI, S.A. AND SUBSIDIARIES
CONSOLIDATED CASH FLOW STATEMENTS FOR THE SIX-MONTH PERIODS ENDING
JUNE 30, 2024 AND JUNE 30, 2023

IN € THOUSANDS*	H1 2024	H1 2023
Cash flows from operating activities		
Profit before income tax	56,142	85,832
Adjustments for non-monetary transactions:		
Amortisation and depreciation	13,446	11,865
Finance income	(100)	(766)
Loss allowance	(1,531)	579
Adjustments for changes in value of derivatives	—	(24)
Gain or loss on derecognition of financial assets and liabilities	(67)	(48)
Finance expenses	644	366
Exchange rate differences	(163)	(166)
Grants, distribution licenses and other deferred income	(397)	(323)
Share of profit/(loss) of joint ventures and associated companies	22	13
Changes in working capital:		
Trade and other receivables	27,042	54,176
Inventories	(16,064)	(40,063)
Other current assets (prepaid expenses)	(1,352)	(2,743)
Trade and other payables	(29,005)	(21,567)
Other collections and payments:		
Cash flow from contract manufacturing services	(13,926)	(23,270)
Proceeds from distribution licenses	608	185
Income tax cash flow	(5,550)	(11,507)
Net cash generated from (used in) operating activities	29,749	52,539
Cash flows from investing activities		
Acquisition of intangible assets	(645)	(173)
Acquisition of property, plant and equipment (not including rights of use)	(18,026)	(17,998)
Proceeds from sale of property, plant and equipment	16	10
Proceeds from sale of financial assets	80	10
Investments in joint ventures and associated companies	(255)	—
Interest received	100	766
Net cash generated from (used in) investing activities	(18,730)	(17,385)
Cash flows from financing activities		
Repayments of financial debt	(16,154)	(6,822)
Proceeds from financial debt	70,158	663
Interest paid	(322)	(186)
Purchase of treasury shares	(52,112)	(48,739)
Reissue of treasury shares	4,097	48,626
Capital contribution in subsidiaries	2,570	171
Net cash generated from (used in) financing activities	8,237	(6,287)
Net (decrease) increase in cash and cash equivalents	19,256	28,867
Cash & cash equivalents at beginning of the period	25,322	124,945
Cash and cash equivalents at end of the period	44,578	153,812

*There has been a limited review of the figures for the first half of 2024 and 2023 by the auditor.

APPENDIX 2

ALTERNATIVE PERFORMANCE MEASURES

In addition to the financial information prepared in accordance with International Financial Reporting Standards (“IFRSs”) taken from our financial statements, this document includes certain alternative performance measures (“APMs”) as defined in the ESMA (European Securities and Markets Authority) Guidelines on Alternative Performance Measures of 5 October, 2015 (ESMA/2015/1415), as well as some non-IFRS financial indicators. The financial measures contained in this document that are considered APMs or non-IFRS financial indicators have been prepared on the basis of the ROVI Group’s financial information but are not defined or set out in detail within the framework of the applicable financial information and have not been audited or reviewed by ROVI’s auditors.

These APMs are considered figures that have been adjusted in respect of those that are presented in accordance with the International Financial Reporting Standards endorsed by the European Union (IFRS-EU), which form the applicable accounting framework for the consolidated financial statements of the ROVI Group. Therefore, the reader should consider them to complement the latter but not to replace them.

We use these APMs and non-IFRS financial indicators to plan, oversee and assess our performance. We consider the APMs and non-IFRS financial indicators to be useful to allow the management team and investors to compare the past or future financial performance, the financial situation and the cash flows. Notwithstanding, these APMs and non-IFRS financial indicators are considered complementary and are not intended to replace IFRS measures. Furthermore, other companies, including some in ROVI’s sector, may calculate such measures differently, which reduces their usefulness for comparative purposes.

This document contains information on the alternative performance measures (APMs) and non-IFRS financial indicators used, including their definitions and a reconciliation between the applicable management indicators and the financial information set out in the consolidated financial statements prepared under IFRSs. The document is available on ROVI’s website and may be accessed on the following link: (<https://www.rovi.es/en/shareholders-investors/financial-business-information>).

In this respect, in accordance with the Guidelines issued by the European Securities and Markets Authority (ESMA), in force since 3 July, 2016, in relation to the transparency of Alternative Performance Measures, ROVI provides below information concerning the APMs it considers significant that are included in this press release:

- **Operating revenue**

This APM shows the revenue that the group generates from its main business activities.

Operating revenue refers to revenue.

- **Other revenue**

Other revenue shows the grants obtained by the Group to develop its R&D&I and other projects.

Other revenue refers to the recognition of government grants on non-financial non-current assets and other.

- **Total revenue**

This APM shows all the group's revenues.

We calculate total revenue as revenue plus the recognition of government grants on non-financial non-current assets and other.

- **Cost of sales**

The cost of sales reflects the cost involved in producing or acquiring the products or services that ROVI sells.

The cost of sales is calculated as the amount of raw materials and consumables used plus that corresponding to the changes in inventories of finished goods and work in progress.

- **Gross profit**

Gross profit is an indicator that measures the direct profit that ROVI obtains from carrying out its income-generating activities.

We calculate gross profit as total revenue less cost of sales.

- **Gross margin or gross profit as % of operating revenue**

This APM is a percentage indicator that measures the direct profit that ROVI obtains from its operating revenue.

We calculate gross margin or gross profit as % of operating revenue as the percentage that the gross profit represents in the revenue (operating revenue).

- **Research & Development ("R&D") Expenses**

R&D expenses reflect expenses related to scientific research and technological development carried out by ROVI.

R&D expenses are calculated as the sum of employee benefits expenses and other operating expenses related to scientific research and technological development.

- **SG&A Expenses**

Selling, General & Administrative (SG&A) Expenses is an indicator that measures expenses related to the general internal operations and management of the company.

SG&A calculated as the amount of employee benefit expenses plus other operating expenses plus work carried out by the Group on non-current assets" minus research & development expenses.

- **EBITDA**

EBITDA (Earnings Before Interest, Tax, Depreciation and Amortization) is an indicator that measures the group's operating profit before interest, taxes, impairment, depreciation and amortization have been deducted. Management uses it to assess the results over time, allowing a comparison with other companies in the sector.

We calculate EBITDA as profit before: taxes, interest, depreciation and amortization.

- **EBITDA margin or EBITDA as % of operating revenue**

This APM is a percentage indicator that measures the operating profit that ROVI obtains from its operating revenue before interest, taxes, impairment, depreciation and amortization are deducted.

We calculate EBITDA margin or EBITDA as % of operating revenue as the percentage that the EBITDA represents in the revenue (operating revenue).

- **EBITDA "Pre-R&D"**

This APM is used by ROVI to show EBITDA from the on-going business.

We calculate EBITDA "Pre-R&D" as EBITDA excluding: R&D expenses and non-recurring income and expenses.

- **EBIT**

EBIT (Earnings Before Interest and Taxes) is an indicator that measures the group's operating profit before interest and tax are deducted. Like EBITDA, Management uses it to assess the results over time, allowing a comparison with other companies in the sector.

We calculate EBIT as profit before: taxes and interest.

- **EBIT margin or EBIT as % of operating revenue**

This APM is a percentage indicator that measures the operating profit that ROVI obtains from its operating revenue before interest and tax are deducted.

We calculate EBIT margin or EBIT as % of operating revenue as the percentage that the EBIT represents in the revenue (operating revenue).

- **EBIT "Pre-R&D"**

This APM is used by ROVI to show EBIT from the on-going business.

We calculate EBIT "Pre-R&D" as operating profit for the period excluding: Research and Development expenses ("R&D") and non-recurring income and expenses.

- **Net profit**

Net profit is an indicator that measures the group's profit for the period.

We calculate Net profit as EBIT plus finance costs-net and income tax.

- **Net profit as % of operating revenue**

This APM is a percentage indicator that measures the profit for the period that ROVI obtains from its operating revenue.

We calculate net profit as % of operating revenue as the percentage that the net profit represents in the revenue (operating revenue).

- **Net profit “Pre-R&D”**

This APM is used by ROVI to show the profit for the period related to the on-going business.

We calculate net profit “Pre-R&D” as EBIT “Pre-R&D” plus:

- Finance costs-net; and
- Income tax. Net profit “Pre-R&D” income tax is calculated by applying the same effective tax rate as reported in the income statement of the period.

- **Gross cash position**

Gross cash position is an indicator that measures the amount of cash the group has at a specific point in time.

We calculate gross cash position as equity securities plus deposits plus financial derivatives plus financial assets at amortised cost plus cash and cash equivalents.

- **Net cash**

Net cash, also measured as financial debt or net debt, is the main indicator used by Management to measure the group’s indebtedness.

It is composed of equity securities, plus deposits, plus financial derivatives, plus financial assets at amortised cost, plus cash and cash equivalents, less current and non-current financial debt.

- **Capex**

Capex is an indicator used to better understand the investments made by the group in its operations.

We calculate Capex as purchases of property, plant and equipment and intangible assets.

- **Capex as % of operating revenue**

This APM is a percentage indicator that measures the group's investments in property, plant and equipment, and intangible assets to its operating revenues.

We calculate Capex as % of operating revenue as the percentage that the purchases of property, plant and equipment and intangible assets represents in the revenue (operating revenue).

- **Free Cash Flow (FCF)**

Free cash flow is an indicator that measures cash flow generation from operating and investment activities and is useful for evaluating the funds available for paying shareholder dividends and servicing debt.

We calculate free cash flow as net cash generated from or used in operating activities less purchases of property, plant and equipment and intangible assets ("Capex") plus proceeds from sale of property, plant and equipment and intangible assets plus interest received.

- **FCF as % of operating revenue**

This APM is a percentage indicator that measures the group's cash flow generation from operating and investment activities relative to its operating revenues.

We calculate FCF as % of operating revenue as the percentage that the free cash flow represents in the revenue (operating revenue).